The Pelvic Floor
& Magnetic Fields.

August 2026 · 9 min read · Evidence Review

Clinic owners and pelvic health physiotherapists are being asked a question that did not exist five years ago: should we put a magnetic stimulation chair in the practice? Patients arrive already using the vocabulary — leaking with a cough or a sneeze, pelvic pain that will not resolve, a heaviness after childbirth — and they expect a professional answer. This article gives it precisely: what the evidence shows, where it stops, and the difference between device categories sold under one marketing umbrella.

What Is Pelvic Floor Magnetic Stimulation, and How Does It Differ from Clinical PEMF?

Extracorporeal magnetic stimulation produces a focused, high-intensity field that induces a nerve current and contracts the pelvic floor muscles — while low-intensity PEMF produces no contraction at all. The difference is physical, not semantic. Magnetic stimulation devices are built as a chair or seat around a single focused coil and operate orders of magnitude above the intensity of a PEMF mat or applicator. Low-intensity PEMF works through an entirely different route: effects on inflammation, oedema and local circulation, with no motor recruitment. Both use a magnetic field, so they are often presented as the same thing. They are not. Each has its own evidence base, its own indications and its own registration category, and conflating them is the most common error in this market.

What Did the Most Recent Meta-Analysis Show for Urinary Incontinence?

A significant improvement in incontinence symptoms and quality of life — alongside no meaningful effect in overactive bladder or chronic pelvic pain. The systematic review and meta-analysis by Yang and colleagues, published in 2025 in Neurourology and Urodynamics (PubMed 40401438), reviewed 24 studies and pooled 14, using the Cochrane RoB 2 tool with a pre-registered protocol (PROSPERO CRD42024526565). On the ICIQ-SF the standardized mean difference was −0.73 (95% CI −1.05 to −0.41); for quality of life, −0.43 (−0.82 to −0.04). The authors qualified their own conclusion: larger, higher-quality randomized trials are needed before efficacy can be claimed for other pelvic floor disorders. What was demonstrated is one diagnosis, not "pelvic floor health" in general.

Is the Device Better Than Pelvic Floor Muscle Training?

In the only randomized trial that compared them directly — no. Dudonienė and colleagues published a randomized controlled trial in 2023 in the Journal of Clinical Medicine (PubMed 37176598), run in an outpatient rehabilitation centre: 68 women enrolled, 48 completed (24 per arm), aged 29–49, with stress urinary incontinence, over six weeks. Both groups improved significantly on the ICIQ-SF and IIQ-7 questionnaires and on perineometry, with medium to large effect sizes — and no significant between-group difference on any measure. For a clinic owner this is the most important line in the literature: the machine does not replace the therapist. It is relevant mainly for patients who cannot voluntarily recruit the muscle, who train incorrectly, or who will not adhere to a programme.

Why Do Two Meta-Analyses Disagree About Chronic Pelvic Pain?

Because they drew on different research databases, and the gap in source quality explains the gap in results. Yang 2025 found no substantial therapeutic effect in chronic pelvic pain. A 2024 meta-analysis by Li and colleagues (PubMed 39262719), covering 8 randomized trials and 636 patients with chronic prostatitis and chronic pelvic pain syndrome, reported a 6.65-point reduction on the NIH-CPSI (95% CI −8.15 to −5.15, p<0.00001) and improved peak urinary flow. The methodological difference is visible: Li pooled Chinese-language regional databases alongside the international ones and published in a lower-tier journal, while Yang drew on PubMed, Cochrane, Web of Science and EMBASE with a registered protocol and systematic bias assessment. The professional recommendation: do not build a treatment promise in chronic pelvic pain on the weaker of the two.

Where Do Low-Intensity PEMF Systems Fit — and What May Be Claimed for Them?

The evidence base for low-intensity PEMF was built in musculoskeletal pain and oedema, not in urinary continence. Our central citation is a 2025 multicenter RCT (PMC11914662), n=91 across five orthopaedic clinics, in which pain fell 36% versus 10% with standard care (p<0.0001) — a finding in joint and soft-tissue pain. In the pelvic region itself there is a single randomized trial of PEMF proper: Elgohary and Tantawy, Cairo University, 2017 (PubMed 28878453), 60 men aged 55–65 with benign prostatic hyperplasia across three arms — PEMF with exercise, PEMF alone, and placebo. Both PEMF arms improved significantly and the combined arm led. That is one small single-centre four-week study — not a basis for an independent indication. PainFree systems are not continence devices and we do not present them as such.

How Do the Three Device Categories Actually Differ?

Parameter	Extracorporeal magnetic stimulation (chair)	Clinical PEMF system	Medical-grade home PEMF device
Mechanism	Induced muscle contraction	Effect on inflammation, oedema, circulation	Same mechanism, lower intensity
Evidence-based primary indication	Urinary incontinence	Musculoskeletal pain and oedema	Musculoskeletal pain and oedema
Proven in overactive bladder	Not demonstrated (Yang 2025)	Not studied	Not studied
Superior to pelvic floor training	Not demonstrated (Dudonienė 2023)	Not applicable	Not applicable
Relative field intensity	Highest of the three	Intermediate	Higher than common consumer home devices, lower than the clinical system
Possible treatment frequency	1–2× weekly in clinic	1–2× weekly in clinic	Daily, even twice daily
Hands-free during session	Yes	Yes	Yes

A fourth category sits outside the table: consumer wellness products — mats and mattresses sold with no defined medical indication. Confusing a medical-grade home device with a consumer product is the single most common patient-side error. The advantage of the home route is not power but frequency: a clinic treats once or twice a week, while at home treatment can run daily — and in chronic conditions cumulative dose is the real difference.

What Does a Sound Purchasing Decision Look Like?

1. Define your actual clinical mix. Count how many stress urinary incontinence patients you saw last quarter — the evidence supports that indication, not pelvic floor disorders in general.
2. Audit what already works. If your pelvic floor training programme is structured and patients adhere to it, the head-to-head trial does not promise you an improvement over it.
3. Separate the two purchases. A continence device and a PEMF system for musculoskeletal pain solve different problems for different audiences; do not weigh them as one budget line.
4. Demand the registration file for the specific model. Regulatory clearance belongs to a model, not to a manufacturer and not to a technology. PEMF devices with FDA 510(k) clearance for pain and oedema exist on the market; ask to see the current certificate for the model offered to you.

70+ Israeli clinics serving a population of 9M — now expanding to the Philippines — most added PEMF as a pain and oedema layer alongside manual therapy, not as a replacement for it.

FAQ

Does pelvic floor magnetic stimulation replace pelvic floor physiotherapy?

No. In the randomized trial that compared the two directly (PubMed 37176598, 48 women completing), both approaches improved symptoms and quality of life to a similar degree, with no significant difference between them. The practical value of the device is for patients who cannot recruit the muscle voluntarily or will not adhere to training — not for replacing the therapist.

Does it help overactive bladder?

The most recent meta-analysis (PubMed 40401438) found no substantial therapeutic effect in overactive bladder, in contrast to the positive finding in urinary incontinence. These are two diagnoses that sound similar to a patient but behave differently. A patient with overactive bladder needs urological assessment, not a treatment promise the evidence does not support.

How many sessions are needed, and how long is each?

Across the reviewed trials, protocols clustered around six weeks of treatment in sessions of roughly 20–30 minutes, twice weekly. Treatment is delivered seated or lying down, through clothing, with no hands-on contact. The exact protocol depends on the referring physician's diagnosis and on the specific device, and is not uniform across models.

What separates a medical-grade home device from a PEMF mat sold online?

A medical-grade home device is medical equipment with defined programmes and a defined indication — stronger than the common consumer home devices worldwide and less intense than the clinical system. A wellness mat or mattress is a consumer product with no defined medical indication. The main advantage of the home route is frequency: treatment can be given daily, even twice daily.

Who must not receive magnetic field treatment?

Anyone with a cardiac pacemaker, defibrillator or active electronic implant, women who are pregnant, and people with epilepsy. Active malignancy, active pelvic infection or unexplained bleeding require assessment before any treatment. Urinary retention or saddle-area sensory change is a red flag requiring urgent neurological assessment.